|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
16.500 -0.060 (-0.362%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Turnover | 20,376,519 | 4.896% | 19,425,533 | 20,383,158 | 21,315,899 | 21,282,131 |
| Cost of Sales | (10,288,189) | 1.627% | (10,123,465) | (10,463,386) | (10,698,520) | (11,578,145) |
| Gross Profit | 10,088,330 | 8.453% | 9,302,068 | 9,919,772 | 10,617,379 | 9,703,986 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (28,123) | -2.126% | (28,734) | (38,038) | (57,976) | (22,860) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 1,135,354 | 22.126% | 929,661 | 841,320 | 1,022,263 | 799,019 | |
| Profit / (Loss) before Taxation | 2,586,571 | -4.852% | 2,718,481 | 1,931,201 | 2,661,640 | 2,358,480 | |
| Taxation | (437,643) | -29.215% | (618,271) | (381,469) | (610,245) | (509,086) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (427,460) | 7.336% | (398,243) | (324,933) | (267,753) | (307,509) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,721,468 | 1.146% | 1,701,967 | 1,224,799 | 1,783,642 | 1,541,885 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/06 RMB(K¥) | 2024/06 RMB(K¥) | 2023/06 RMB(K¥) | 2022/06 RMB(K¥) | |
| Net Finance Costs / (Income) | 472,162 | -3.508% | 489,326 | 520,576 | 431,881 | 320,482 |
| Depreciation & Amortisation | 1,878,267 | 8.015% | 1,738,891 | 1,546,990 | 1,565,006 | 1,064,356 |
| Directors' Emoluments | -- | -- | -- | -- | -- | -- |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| Auditor's Opinion Status | N/A | -- | N/A | N/A | N/A | N/A |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/06 | 2024/06 | 2023/06 | 2022/06 | |
| EPS (cts) | 65.000 | 1.563% | 64.000 | 46.000 | 67.000 | 60.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | -- | -- | -- | -- |
| NBV per share ($) | 18.447 | -- | 17.942 | 17.561 | 16.996 | -- |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,721,468 |
| %Change | 1.146% |
| EPS / (LPS) | RMB 0.650 |
| NBV Per Share (¥) | RMB 18.447 |